The Female Health Company Added to Russell Microcap(R) Index

The Russell Microcap(R) Index measures the performance of the microcap segment, representing less than 3% of the U.S. equity market. The Russell Microcap(R) Index includes the smallest 1,000 securities in the small-cap Russell 2000(R) Index plus the next 1,000 securities.

"We are very pleased to learn that The Female Health Company has qualified for inclusion in the Russell Microcap(R) Index and believe that this reflects our Company's continued positive momentum," stated O.B. Parrish, Chief Executive Officer of The Female Health Company. "Membership in the Russell Microcap(R) Index is based upon market capitalizations of qualifying companies, and The Female Health Company's 'market cap' has increased from approximately $58 million at the end of June 2007 to approximately $72 million currently. Russell is an industry leader for stock indexes, and we expect our inclusion in the Russell Microcap(R) Index to generate greater interest in our stock among institutional investors."

The Russell family of U.S. indexes is designed to be a comprehensive representation of the investable U.S. equity market. These indexes are value- weighted and include only common stocks belonging to corporations that are incorporated inthe United States and its territories. Final membership lists for the Russell 3000(R), Russell 1000(R), Russell 2000(R), Russell Global, Russell Midcap(R) and Russell Microcap(R) indexes were posted to the Russell Investments website on June 30, 2008.

Real-time market analysis on the Russell indexes is available at http://www.russell.com/indexes/performance/real_time_market_analysis.asp, and a preliminary list of additions to the Russell Microcap(R) Index is currently posted on http://www.russell.com.

About Russell Investments

Russell Investments aims to improve financial security for people by providing strategic advice, world-class implementation, state-of-the-art performance benchmarks, and a range of institutional-quality investment products. With more than $200 billion in assets under management, Russell serves individual, institutional and advisor clients in more than 40 countries. Russell provides access to some of the world's best money managers. It helps investors put this access to work in corporate defined benefit and defined contribution plans, and in the life savings of individual investors. Russell's indexes are unmanaged and cannot be invested in directly. Headquartered inTacoma, Washington, Russell has principal offices inAmsterdam,Auckland,Johannesburg,London,Melbourne,New York,Paris,San Francisco,Seoul,Singapore,Sydney,Tokyo andToronto.

About The Female Health Company

The Female Health Company (FHC), headquartered inChicago, IL, is the maker of the FC Female Condom (FC1 and FC2), a revolutionary option offering women dual protection against both sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. FHC was created as a worldwide company in February 1996 with the purchase of Chartex Resources Ltd., the holder of exclusive worldwide rights to FC1. The Company holds exclusive product and technology patents for FC1 inthe United States,Australia,Brazil,Canada, France,Germany,Italy,Spain, theUnited Kingdom,the People's Republic of China,South Korea andJapan. Patents are pending for FC2. FHC is the sole manufacturer and marketer of the FC1 and FC2 female condoms in the world. The Female Health Company and its partners currently market the Female Condom under FC Female Condom(R), FC2 Female Condom(R), Reality(R), Femidom(R), Femy(R), and Care(R) in the rest of the world. For more information about the Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org . If you would like to be added to the Company's e-mail alert list, please send an e-mail to FHCInvestor@femalehealthcompany.com .

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

The statements in this release which are not historical fact are "forward- looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this release may be identified by the use of forward-looking words or phrases such as "anticipate," "believe," "could," "expect," "intend," "may," "planned," "potential," "should," "will," "would" or the negative of those terms or other words of similar meaning. These statements are based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, and are made as of the date of this release. The Company assumes no obligation to update any forward-looking statements contained in this release as a result of new information or future events, developments or circumstances. Such forward- looking statements are inherently subject to known and unknown risks and uncertainties. The Company's actual results and future developments could differ materially from the results or developments expressed in, or implied by, these forward-looking statements. Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, but are not limited to, the following: product demand and market acceptance; competition in the Company's markets and the risk of new competitors and new competitive product introductions; the Company's reliance on its international partners in the consumer sector and on the level of spending on the female condom by country governments, global donors and other public health organizations in the global public sector; the economic and business environment and the impact of government pressures; risks involved in doing business on an international level, including currency risks, regulatory requirements, political risks, export restrictions and other trade barriers; the Company's production capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communication and Securities and Exchange Commission filings, including the Company's Form 10-KSB for the fiscal year ended September 30, 2007. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.

SOURCE The Female Health Company

Copyright © 2008, PRNewswire
Copyright © 2008, NewsBlaze, Daily News

Tags: Healthcare, Pharmaceuticals, Banking and Finance, Health, , illinois

   _   _

         

Is your favorite bookmark site missing? Ask for it.